Efgartigimod
Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists.
Key: IV: Intravenous
SC: Subcutaneous
+ AZA: Azacitidine
+VEN: Venetoclax
Neurology
Hematology / Rheumatology
Dermatology
Nephrology
Program
Clinical trial
Preclinical
Phase 1
Proof of Concept
Registrational
Approved
Generalized Myasthenia Gravis (gMG)
IV
SC
Primary Immune Thrombocytopenia (ITP)
- Primary ITP is a rare, often chronic disorder where IgG antibodies cause reduced numbers of platelets leading to an increased risk of bleeding and bruising
- IV efgartigimod and SC efgartigimod
IV
SC
Pemphigus Vulgaris and Foliaceus (PV & PF)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- CIDP is a rare, chronic disorder where damage to peripheral nerves, which may be caused by antibodies, results in progressive weakness and a loss of feeling in the arms and legs
- SC efgartigimod
Bullous Pemphigoid (BP)
Idiopathic Inflammatory Myopathies (Myositis)
Post-COVID Postural Orthostatic Tachycardia Syndrome (PC-POTS)
Primary Sjogren’s Syndrome (pSS)
Membranous Nephropathy (MN)
Lupus Nephritis (LN)
Thyroid Eye Disease (TED)
Antibody Mediated Rejection (AMR)
ANCA-Associated Vasculitis (AAV)
Clinical trials
argenx is running clinical trials of efgartigimod, in development for a range of severe autoimmune diseases. For more info on clinical trials with efgartigimod, please click the link below.
Proposed
Mechanism
of Action
